ANNX

Annexon, Inc.

Fundamental data last updated:August 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/13/2026

Business Summary

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

 


Analyze ANNX on TradingView

VALUATION

P/E

-5.31

Market Cap ($M USD)

$642.23M

Forward P/E

1.99

PEG

0.01

PRICE TO SALES

0.00

PRICE TO BOOK

5.10

EV / EBITDA

-2.46

5-Year Average P/E

Free Cash Flow Yield

-28.52%

DCF Value

$0.79

Graham Number

N/A

Price to FCF

-3.51

EV to FCF

-2.69

Earnings Yield

-18.84%

FCF Yield

-28.52%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

-0.95%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.01

Next Year EPS Growth Estimate

$2.70

Next Year Revenue Growth Estimate

$1.06B

Return on Equity (ROE)

-101.19%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.12

Piotroski F-Score

1

Altman Z-Score

-0.19

Return on Invested Capital (ROIC)

-90.35%

Current Ratio

6.35

Quick Ratio

6.35

Net Debt to EBITDA

0.75

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-0.94

REVENUE PER SHARE

$0.00

Analyze ANNX on TradingView

Gainseekers Quantitative Analysis

Summary

Annexon, Inc. presents a perplexing valuation scenario. Despite a forward P/E of 2.11 suggesting potential undervaluation, the stock’s DCF value is alarmingly low, indicating market skepticism about future cash flows. The Altman Z-score of 0.21 signals distress, raising red flags about financial stability. Meanwhile, the negative earnings yield and ROIC underscore a challenging profitability landscape. The market seems to be pricing in significant risk, potentially misaligned with the company’s growth prospects.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Annexon is strategically positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns well with technological shifts. However, execution will be key to capitalizing on these opportunities.

The Bull Case

For the optimistic investor, Annexon's forward PEG ratio of 0.0057 is a beacon of deep value, suggesting the stock is priced attractively relative to its growth potential. The company's low debt-to-equity ratio of 0.12 indicates prudent financial management, while a robust current ratio of 6.35 highlights liquidity strength. Despite a low Piotroski F-Score, the potential for explosive sales growth next year could drive substantial returns for those willing to take the risk.

The Bear Case

Annexon's financial health is fraught with challenges. The negative EV to EBITDA and price to FCF ratios reflect poor cash flow generation, while the price-to-book ratio of 5.40 suggests overvaluation. The stock's proximity to its 52-week high raises concerns about technical overextension. With zero gross profit margin and a dismal ROIC, the company struggles to demonstrate operational efficiency.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$11.50

Institutional Ownership %

1-Year Beta

1.22

Insider Buying % (6 Mo)

Distance to 52-Week High

33.71%

Distance to 52-Week Low

65.55%

EARNINGS SURPRISE %

23.33%

50-DAY SMA

$5.64

200-DAY SMA

$4.52

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.